Influenza vaccination reduces cardiovascular events in patients with acute coronary syndrome

Aims Influenza infection has been shown to accentuate the progression of atherosclerosis and precipitate the occurrence of acute coronary syndrome (ACS). However, the protective effects of the influenza vaccine on cardiovascular events are still inconclusive. Methods and results The study was a pros...

Full description

Saved in:
Bibliographic Details
Main Authors: Phrommintikul A., Kuanprasert S., Wongcharoen W., Kanjanavanit R., Chaiwarith R., Sukonthasarn A.
Format: Article
Language:English
Published: 2014
Online Access:http://www.scopus.com/inward/record.url?eid=2-s2.0-79953222097&partnerID=40&md5=5643d4eecbc33a2b8e73e19935caeb17
http://www.ncbi.nlm.nih.gov/pubmed/21289042
http://cmuir.cmu.ac.th/handle/6653943832/3010
Tags: Add Tag
No Tags, Be the first to tag this record!
Institution: Chiang Mai University
Language: English
id th-cmuir.6653943832-3010
record_format dspace
spelling th-cmuir.6653943832-30102014-08-30T02:25:39Z Influenza vaccination reduces cardiovascular events in patients with acute coronary syndrome Phrommintikul A. Kuanprasert S. Wongcharoen W. Kanjanavanit R. Chaiwarith R. Sukonthasarn A. Aims Influenza infection has been shown to accentuate the progression of atherosclerosis and precipitate the occurrence of acute coronary syndrome (ACS). However, the protective effects of the influenza vaccine on cardiovascular events are still inconclusive. Methods and results The study was a prospective randomized open with blinded endpoint (PROBE) study. The 439 patients who had been admitted due to ACS within 8 weeks were enrolled and randomly allocated to receive inactivated influenza vaccine in the vaccine group and no treatment in the control group. All patients were treated with the standard therapy including revascularization according to primary cardiologists. The primary endpoint, which was the combined major cardiovascular events, including death, hospitalization from ACS, hospitalization from heart failure, and hospitalization from stroke, occurred less frequently in the vaccine group than the control group [9.5 vs. 19.3%, unadjusted HR 0.70 (0.57-0.86), P = 0.004]. There was no significant difference in the incidence of cardiovascular death between the vaccine and control groups [2.3 vs. 5.5, unadjusted HR 0.39 (0.14-1.12), P = 0.088]. Conclusion The influenza vaccine reduced major cardiovascular events in patients with ACS. Therefore, it should be encouraged as a secondary prevention in this group of patients. © 2011 The Author. 2014-08-30T02:25:39Z 2014-08-30T02:25:39Z 2011 Article 0195668X 10.1093/eurheartj/ehr004 EHJOD http://www.scopus.com/inward/record.url?eid=2-s2.0-79953222097&partnerID=40&md5=5643d4eecbc33a2b8e73e19935caeb17 http://www.ncbi.nlm.nih.gov/pubmed/21289042 http://cmuir.cmu.ac.th/handle/6653943832/3010 English
institution Chiang Mai University
building Chiang Mai University Library
country Thailand
collection CMU Intellectual Repository
language English
description Aims Influenza infection has been shown to accentuate the progression of atherosclerosis and precipitate the occurrence of acute coronary syndrome (ACS). However, the protective effects of the influenza vaccine on cardiovascular events are still inconclusive. Methods and results The study was a prospective randomized open with blinded endpoint (PROBE) study. The 439 patients who had been admitted due to ACS within 8 weeks were enrolled and randomly allocated to receive inactivated influenza vaccine in the vaccine group and no treatment in the control group. All patients were treated with the standard therapy including revascularization according to primary cardiologists. The primary endpoint, which was the combined major cardiovascular events, including death, hospitalization from ACS, hospitalization from heart failure, and hospitalization from stroke, occurred less frequently in the vaccine group than the control group [9.5 vs. 19.3%, unadjusted HR 0.70 (0.57-0.86), P = 0.004]. There was no significant difference in the incidence of cardiovascular death between the vaccine and control groups [2.3 vs. 5.5, unadjusted HR 0.39 (0.14-1.12), P = 0.088]. Conclusion The influenza vaccine reduced major cardiovascular events in patients with ACS. Therefore, it should be encouraged as a secondary prevention in this group of patients. © 2011 The Author.
format Article
author Phrommintikul A.
Kuanprasert S.
Wongcharoen W.
Kanjanavanit R.
Chaiwarith R.
Sukonthasarn A.
spellingShingle Phrommintikul A.
Kuanprasert S.
Wongcharoen W.
Kanjanavanit R.
Chaiwarith R.
Sukonthasarn A.
Influenza vaccination reduces cardiovascular events in patients with acute coronary syndrome
author_facet Phrommintikul A.
Kuanprasert S.
Wongcharoen W.
Kanjanavanit R.
Chaiwarith R.
Sukonthasarn A.
author_sort Phrommintikul A.
title Influenza vaccination reduces cardiovascular events in patients with acute coronary syndrome
title_short Influenza vaccination reduces cardiovascular events in patients with acute coronary syndrome
title_full Influenza vaccination reduces cardiovascular events in patients with acute coronary syndrome
title_fullStr Influenza vaccination reduces cardiovascular events in patients with acute coronary syndrome
title_full_unstemmed Influenza vaccination reduces cardiovascular events in patients with acute coronary syndrome
title_sort influenza vaccination reduces cardiovascular events in patients with acute coronary syndrome
publishDate 2014
url http://www.scopus.com/inward/record.url?eid=2-s2.0-79953222097&partnerID=40&md5=5643d4eecbc33a2b8e73e19935caeb17
http://www.ncbi.nlm.nih.gov/pubmed/21289042
http://cmuir.cmu.ac.th/handle/6653943832/3010
_version_ 1681419967686246400